Latest news

• ASCO data back up Merck & Co's dominance in lung cancer

  That includes Roche, which reported updated data from the IMpower131 study at ASCO showing a significant 29% improvement in the risk of disease worsening or death for its PD-L1 inhibitor

• Bluebird and Celgene BCMA CAR-T kicks off ASCO

  First-line NSCLC is also the focus for other much-anticipated new trials, including progression-free survival figures from Roche’s IMpower131 study of PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin

• Immuno-oncology at ASCO: survival data, combinations and new indications

  as new PFS data from the IMpower131 trial of Tecentriq and chemotherapy in first-line squamous NSCLC.

• Roche eyes September FDA verdict for triple NSCLC therapy

  Meanwhile, Roche reported interim data from the IMpower131 trial of Tecentriq plus chemotherapy in first-line squamous NSCLC in March, but while the initial read-out was positive for PFS, it

• Another Tecentriq win for Roche as Avastin combo boosts survival

  Just last week, the company reported data from the IMpower131 trial showing that combining Tecentriq with standard first-line chemotherapy in patients with the squamous form of advanced NSCLC resulted in